MX2021014944A - Metodos para tratar cancer usando inhibidores de prmt5. - Google Patents

Metodos para tratar cancer usando inhibidores de prmt5.

Info

Publication number
MX2021014944A
MX2021014944A MX2021014944A MX2021014944A MX2021014944A MX 2021014944 A MX2021014944 A MX 2021014944A MX 2021014944 A MX2021014944 A MX 2021014944A MX 2021014944 A MX2021014944 A MX 2021014944A MX 2021014944 A MX2021014944 A MX 2021014944A
Authority
MX
Mexico
Prior art keywords
days
methods
administering
prmt5
subsequent
Prior art date
Application number
MX2021014944A
Other languages
English (en)
Inventor
Dirk Brehmer
Tongfei Wu
Hong Xie
Hillary Joy Millar Quinn
Kathryn Elizabeth Packman
Nahor Haddish-Berhane
Geert S J Mannens
Junguo Zhou
Anthony T Greway
Yue Guo
Josh Lauring
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2021014944A publication Critical patent/MX2021014944A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona métodos para tratar a un paciente humano a quien se le diagnosticó un cáncer, que comprende administrar una cantidad terapéuticamente eficaz de un inhibidor de PRMT5 (proteína arginina metiltransferasa 5), ciertos métodos comprenden (i) administrar al paciente dosis iniciales de al menos aproximadamente 0.1 mg por día del inhibidor de PRMT5 que es (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquino lina-7-il)etil)-5-(4-amino-7H-pirrolo[2,3-d]pirimidina-7-il)ciclo pentano-1,2-diol o una sal o solvato de adición farmacéuticamente aceptable de este durante un período de dosificación inicial de aproximadamente 5 a aproximadamente 21 días; y (ii) administrar al paciente dosis posteriores de al menos aproximadamente 0.1 mg por día del inhibidor de PRMT5 durante uno o más periodos de dosificación posteriores de aproximadamente 5 a aproximadamente 21 días cada uno. En estos métodos, un primer periodo de dosificación posterior está separado en el tiempo desde el periodo de dosificación inicial por al menos aproximadamente 5 días y los periodos posteriores de dosificación están separados en tiempo entre sí por al menos aproximadamente 5 15 días.
MX2021014944A 2019-06-06 2020-06-05 Metodos para tratar cancer usando inhibidores de prmt5. MX2021014944A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962858076P 2019-06-06 2019-06-06
EP19193850 2019-08-27
PCT/EP2020/065639 WO2020245365A1 (en) 2019-06-06 2020-06-05 Methods of treating cancer using prmt5 inhibitors

Publications (1)

Publication Number Publication Date
MX2021014944A true MX2021014944A (es) 2022-01-24

Family

ID=70922068

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014944A MX2021014944A (es) 2019-06-06 2020-06-05 Metodos para tratar cancer usando inhibidores de prmt5.

Country Status (15)

Country Link
US (2) US11571437B2 (es)
EP (1) EP3980019A1 (es)
JP (1) JP2022535406A (es)
KR (1) KR20220017989A (es)
CN (1) CN113966232A (es)
AU (1) AU2020286961A1 (es)
BR (1) BR112021024469A2 (es)
CA (1) CA3142825A1 (es)
IL (1) IL288665A (es)
JO (1) JOP20210320A1 (es)
MA (1) MA56095A (es)
MX (1) MX2021014944A (es)
SG (1) SG11202112439YA (es)
TW (1) TW202112375A (es)
WO (1) WO2020245365A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022153161A1 (en) * 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
CN115161341B (zh) * 2022-06-10 2023-07-21 中国人民解放军军事科学院军事医学研究院 一种胃窦浸润性肠型胃癌小鼠模型的构建方法与应用
WO2024118943A2 (en) * 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
US7034147B2 (en) 2001-11-29 2006-04-25 Irm Llc Nucleoside analog libraries
US7144871B2 (en) 2002-02-19 2006-12-05 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
US20060167241A1 (en) 2003-07-15 2006-07-27 Mitsui Chemicals, Inc. Method for synthesizing cyclic bisdinucleoside
JP2007537999A (ja) 2003-12-19 2007-12-27 コローニス ファーマシューティカルズ インコーポレイテッド 変異原性複素環
WO2006078752A2 (en) 2005-01-21 2006-07-27 Methylgene, Inc. Inhibitors of dna methyltransferase
WO2008001101A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
AU2009298802A1 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
MX2012007026A (es) 2009-12-18 2013-03-18 Joslin Diabetes Center Inc Compuestos que promueven la replicacion de celula beta y metodos de su uso.
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
CA2819620A1 (en) 2010-12-03 2012-06-21 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
JP5906253B2 (ja) 2010-12-16 2016-04-20 アッヴィ・インコーポレイテッド 抗ウイルス性化合物
ES2587512T3 (es) 2011-04-04 2016-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Derivados de 2'-O-aminooximetil nucleósido para su uso en la síntesis y modificación de nucleósidos, nucleótidos y oligonucleótidos
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
US20140100184A1 (en) 2012-08-31 2014-04-10 Baylor College Of Medicine Selective inhibitors of histone methyltransferase dot1l
CA2894130A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9611257B2 (en) 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
HUE040323T2 (hu) 2012-12-21 2019-02-28 Epizyme Inc PRMT5-inhibitorok és alkalmazásaik
WO2014145214A2 (en) * 2013-03-15 2014-09-18 Ohio State Innovation Foundation Inhibitors of prmt5 and methods of their use
JP6510539B2 (ja) 2014-01-09 2019-05-08 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン 置換ベンゾオキサジン及び関連化合物
US20170198006A1 (en) 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9683003B2 (en) 2014-07-01 2017-06-20 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
CR20170384A (es) 2015-02-24 2017-11-16 Pfizer Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
TW202321249A (zh) 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
EP3426664B1 (en) 2016-03-10 2021-06-30 Janssen Pharmaceutica NV Substituted nucleoside analogues for use as prmt5 inhibitors
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
US11098062B2 (en) 2016-10-03 2021-08-24 Janssen Pharmaceutica Nv Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
PE20191359A1 (es) 2017-02-27 2019-10-01 Janssen Pharmaceutica Nv Uso de biomarcadores en la identificacion de pacientes con cancer que seran sensibles al tratamiento con un inhibidor de prmt5
US11059850B2 (en) 2017-12-08 2021-07-13 Janssen Pharmaceutica Nv Spirobicyclic analogues

Also Published As

Publication number Publication date
WO2020245365A1 (en) 2020-12-10
BR112021024469A2 (pt) 2022-01-18
IL288665A (en) 2022-02-01
AU2020286961A1 (en) 2022-02-03
TW202112375A (zh) 2021-04-01
MA56095A (fr) 2022-04-13
EP3980019A1 (en) 2022-04-13
US20200384006A1 (en) 2020-12-10
US20230241087A1 (en) 2023-08-03
KR20220017989A (ko) 2022-02-14
SG11202112439YA (en) 2021-12-30
CN113966232A (zh) 2022-01-21
JOP20210320A1 (ar) 2023-01-30
CA3142825A1 (en) 2020-12-10
JP2022535406A (ja) 2022-08-08
US11571437B2 (en) 2023-02-07

Similar Documents

Publication Publication Date Title
MX2021014944A (es) Metodos para tratar cancer usando inhibidores de prmt5.
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
MX2021009199A (es) Conjugado de farmaco de dos ligandos y uso del mismo.
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
RU2014144254A (ru) Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
MX2021002042A (es) Inhibidores de arginasa y sus metodos de uso.
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
EP4410295A3 (en) Use of vibegron to treat overactive bladder
JOP20210185A1 (ar) مركبات هالو-آلِّيلامين واستخدامها
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
MX2024000807A (es) Inhibidor de aak1 y uso de este.
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
WO2020132560A3 (en) Compositions and methods for cancer therapy
MX2021000349A (es) Administracion de un inhibidor de la enzima activadora de sumo y anticuerpos anti-cd20.
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
CA2868024A1 (en) Methods of treating cancer using aurora kinase inhibitors
EA202193330A1 (ru) Способы лечения рака с использованием ингибиторов prmt5
MX2022015659A (es) Compuesto de alquenil pirimidina, metodo de preparacion del mismo y aplicacion del mismo.
WO2022061155A9 (en) Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7
EA202190748A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы с цинк-связывающей группировкой
RU2015152175A (ru) Комбинация ro5503781, капецитабина и оксалиплатина для терапии рака